{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-23-000026","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.485618+00:00","generated_at":"2026-06-16T01:25:03.254669+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"10x Genomics Q1 revenue $134.3M (+17% YoY); net loss $50.7M; raises FY2023 guidance to $590-$610M","bullets":["Revenue $134.3M (+17% YoY); spatial portfolio drove growth, Xenium in first full launch quarter.","Net loss $50.7M vs $42.4M in prior year; operating loss $52.0M incl $42.1M stock-based comp.","Gross margin 73% (down from 78%) due to product mix and inventory write-downs.","Raised FY2023 revenue guidance to $590-610M (prev $580-600M); 14-18% growth.","Cash and marketable securities $418.3M as of March 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-23-000026","json":"https://secwatch.observer/filing/0001770787-23-000026.json","markdown":"https://secwatch.observer/filing/0001770787-23-000026.md","text":"https://secwatch.observer/filing/0001770787-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000026/0001770787-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000026/txg-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:25:03.254669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fd61177b7ea554f92873ee6ec962554f5bc649e","claim":"10x Genomics, Inc. reported first quarter ended March 31, 2023 results: revenue $134.3 million, net income $50.7 million. Guidance raised.","evidence_excerpt":"PLEASANTON, Calif. May 3, 2023 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2023. Recent Highlights • Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022. • Surpassed 5,000 customer publications using 10x Genomics products, demonstrating the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000026/0001770787-23-000026-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$134.3 million"},{"label":"Net income","value":"$50.7 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}